Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 06, 2015 3:13 PM ET

Biotechnology

Company Overview of Receptos, Inc.

Company Overview

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics for immune disorders. Its lead product includes RPC1063, an oral sphingosine 1-phosphate 1 receptor modulator that is in Phase II portion of Phase II/III studies for the treatment of relapsing multiple sclerosis; and is in Phase II studies to treat ulcerative colitis. The company is also developing RPC4046, a monoclonal antibody, which is in Phase II studies for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positiv...

10835 Road to the Cure

Suite 205

San Diego, CA 92121

United States

Founded in 2008

68 Employees

Phone:

858-652-5700

Fax:

858-587-2659

Key Executives for Receptos, Inc.

Chief Executive Officer, President and Director
Age: 56
Total Annual Compensation: $451.6K
Chief Financial Officer and Principal Accounting Officer
Age: 44
Total Annual Compensation: $254.8K
Chief Medical officer
Age: 44
Total Annual Compensation: $364.3K
Compensation as of Fiscal Year 2013.

Receptos, Inc. Key Developments

Receptos, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Receptos, Inc. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported loss from operations of $37,159,000 against $15,099,000 a year ago. Net loss attributable to common stockholders was $38,151,000 or $1.32 per basic and diluted share against $15,244,000 or $0.86 per basic and diluted share a year ago. For the full year, the company reported loss from operations of $111,570,000 against $47,893,000 a year ago. Net loss attributable to common stockholders was $114,970,000 or $4.63 per basic and diluted share against $50,376,000 or $4.23 per basic and diluted share a year ago. Collaborative revenue was $5,900,000 against $4,641,000 a year ago.

Receptos, Inc. to Report Q4, 2014 Results on Mar 03, 2015

Receptos, Inc. announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Mar 03, 2015

Receptos, Inc., Q4 2014 Earnings Call, Mar 03, 2015

Receptos, Inc., Q4 2014 Earnings Call, Mar 03, 2015

Similar Private Companies By Industry

Company Name Region
Heartland Plant Innovations Inc. United States
Fast PCR Diagnostics United States
Wellstat Biologics Corporation United States
DENALI BioTechnologies, Inc. United States
Fibercell Systems Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Receptos, Inc., please visit www.receptos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.